Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic

  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Valneva Se ADR (NQ: VALN )

24.41 +0.59 (+2.49%)
Streaming Delayed Price Updated: 3:53 PM EDT, May 27, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 7,388
Open 24.14
Bid (Size) 24.41 (2)
Ask (Size) 26.55 (2)
Prev. Close 23.82
Today's Range 24.00 - 24.71
52wk Range 19.45 - 67.84
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
The Daily Biotech Pulse: Third FDA Rejection For Verrica's Skin Disease Drug, Assembly Bio Terminates Hepatitis B Virus Pact, Consistency Data For Valneva's Chikungunya Vaccine
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
The Daily Biotech Pulse: Valneva's COVID-19 Vaccine Filing Accepted By EMA, Enanta's RSV Candidate Fails, Orphan Drug Tag For Mersana's Gastric Cancer Candidate
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga

Performance

YTD
-52.12%
-52.12%
1 Month
-6.92%
-6.92%
3 Month
-26.93%
-26.93%
6 Month
-59.04%
-59.04%
1 Year
+0.02%
+0.02%

More News

Read More
EU Says Final Decision Yet To Be Taken On Terminating Valneva COVID-19 Vaccine Deal
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
Via Benzinga
Why Valneva's Shares Are Plunging Today Premarket
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga
73 Biggest Movers From Yesterday
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Valneva - Pfizer Post Encouraging Data From Lyme Disease Vaccine Candidate
Via Benzinga
Valneva Shares Jump As Its COVID-19 Vaccine Receives Conditional Approved In UK
Via Benzinga
Read Why Valneva's Stock Gained 7% Today
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Via InvestorPlace
How To Attend Valneva Q1 2022 Earnings Conference Call
Via Benzinga
The Daily Biotech Pulse - Tuesday, April,26
Via Talk Markets
The Daily Biotech Pulse: Protagonist's Ulcerative Colitis Study Disappoints, Gilead's Remdesivir Approved For Pediatric COVID-19 Patients, FDA Gives Nod To Gamida's Cell Therapy Trial, Fast Track Tag For Vascular Biogenics Ovarian Cancer Gene Therapy
Via Benzinga
Valneva and Pfizer Report Positive Phase 2 Pediatric Data for Lyme Disease Vaccine Candidate
From Pfizer Inc.
Via Business Wire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Valneva Receives More Questions From European Regulator For Its COVID-19 Vaccine, Shares Fall
Via Benzinga
Britain Approves Moderna's COVID-19 Vaccine For Kids Aged 6-11 Years
Via Benzinga
The Daily Biotech Pulse: Pfizer-BioNTech COVID-19 Booster Data In Kids, Regeneron's COVID-19 Therapy Decision Pushed, Protagonist's Rusfertide Breakthrough Tag Update And More
Via Benzinga
European Recommendation On Valneva's COVID-19 Shot Pushed Into April
Via Benzinga
The Daily Biotech Pulse: Valneva Gains On COVID Shot Regulatory Update, Lucira Health And Clearside Jump On Earnings, BeiGene Drug Snags Approval In China
Via Benzinga
Earnings Scheduled For March 24, 2022
Via Benzinga
The Daily Biotech Pulse: Moderna Outlines Steps For mRNA Tech Advancement, Voyager-Novartis Strike Licensing Deal, Valneva Reports Positive Chikungunya Shot Readout
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.